Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next-generation systemic therapies. This update provides recommendations for its application in the era of targeted therapies, with an emphasis on efficiency and patient-centered care.